Related Experiment Video
Updated: Sep 28, 2026

Optimized Griess Reaction for UV-Vis and Naked-eye Determination of Anti-malarial Primaquine
Published on: October 11, 2019
Sitamaquine (GlaxoSmithKline/Walter Reed Army Institute)
1cly@welwyn11.freeserve.co.uk
Abstract:
Sitamaquine (WR-6026) is an orally active 8-aminoquinoline analog in development by the Walter Reed Army Institute, in collaboration with GlaxoSmithKline (formerly SmithKline Beecham), for the potential treatment of visceral leishmaniasis. Phase III trials for the treatment of visceral leishmaniasis had been initiated by March 2002, at which time GlaxoSmithKline hoped to file an MAA in 2003. By 1999, the compound had also undergone phase I trials in HIV-infected individuals for the treatment of Pneumocystis carinii infection. Preclinical studies have been conducted in primates and rodents for the potential treatment of Babesia microti infection.
Related Concept Videos
Antiprotozoal Agents
Rocky Mountain Spotted Fever
Malaria
American Trypanosomiasis

